Todd Michael Cooper, DO

Todd Michael Cooper, DO

Specialties

  • Children's Title: Director of the Pediatric Leukemia/Lymphoma Program and Co-Director of the High-Risk Leukemia Program
  • Foundation Title: Evans Family Endowed Chair in Pediatric Cancer
  • Research Center: Ben Towne Center for Childhood Cancer Research
  • On Staff Since: February 2015

  • Biography

    Todd M. Cooper, DO, is an attending physician at Seattle Children's Hospital, Professor of Pediatrics at the University of Washington School of Medicine, and Evan's Family Endowed Chair in Pediatric Cancer. Dr. Cooper is the Director of the Pediatric Leukemia/Lymphoma Program and Co-Director of the High-Risk Leukemia Program.

    Dr. Todd Cooper's interests and expertise focus on the development of new therapeutic strategies for the treatment of acute leukemia in children. Prior to coming to Seattle, Dr. Cooper developed and provided leadership for Phase I/Developmental Therapeutics programs at the University of Alabama at Birmingham and Children's Healthcare of Atlanta/Emory University.

    Dr. Cooper has led Phase I studies of new agents for relapsed acute leukemia in a variety of national consortia including the Therapeutic Advances for Childhood Leukemia (TACL) Consortium, Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC), and the Children's Oncology Group (COG) Consortium. Dr. Cooper serves as the chair of the COG Acute Myeloid Leukemia (AML) New Agents Committee and actively collaborates internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia. Dr. Cooper leads COG AAML1831, a COG Phase III study for newly diagnosed children with AML.

    Dr. Cooper is also the clinical trial lead for a Leukemia/Lymphoma Society-funded master trial for relapsed pediatric acute leukemia (PedAL). This international trial will match children with novel targeted therapies based on centralized next generation genomic sequencing. These opportunities have allowed him to engage with the FDA and EMA in discussing individual new drugs and general clinical trial designs for children with relapsed acute leukemia. He is intimately involved in the selection of new agents, designing and leading clinical trials, all with the goal of bringing positive change to the therapy of children diagnosed with AML both nationally and internationally.

    Board Certification(s)

    Pediatric Hematology-Oncology

    Education

    Nova Southeastern University, Davie, FL

    Residency

    University of South Alabama College of Medicine, Mobile, AL

    Fellowship

    University of Texas MD Anderson Cancer Center, Houston, TX

    Research Focus Area

    Cancer biology

  • Related Resources

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate(testimonial.date) }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}

  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}

  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}

  • Clinical Trials and Research

    {{ item.t }}

    {{ item.st }}

    {{ item.obj }}

    Condition(s): {{ item.con }} Phase: {{ item.ph }} Clinicaltrials.gov ID: {{ item.nct }}

    No clinical trials found for Todd Michael Cooper, DO.